Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:DHHS, EACS, IAS, and WHO recommendations for first-line ARTVirologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National SurveyPolypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairmentCardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ARTPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal Medicine  Chair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida  Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenCopenhagen, DenmarkDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark  Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3miT6qHSee the entire program at: https://bit.ly/2TXTYWx  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.